Press

Pear Therapeutics to Present at Jefferies 2018 Healthcare Conference

Boston, May 29, 2018 – Pear Therapeutics, Inc., the leader in prescription digital therapeutics, today announced that Corey McCann, M.D., Ph.D., President and CEO, will present at the Jefferies 2018 Healthcare Conference on Tuesday, June 5 at 2:30 p.m. EST at the Grand Hyatt New York.

Click here for the full press release.

 

Pear Therapeutics to Present at UBS Global Healthcare Conference

Boston, May 17, 2018 – Pear Therapeutics, Inc., the leader in prescription digital therapeutics, today announced that Christopher D.T. Guiffre, J.D., M.B.A., Chief Financial Officer and Chief Operating Officer, will present at the UBS Global Healthcare Conference on Tuesday, May 22 at 4:00 p.m. EST at the Grand Hyatt New York.

Click here for the full press release.

Pear Therapeutics and Sandoz Announce Deal to Commercialize Prescription Digital Therapeutics

BOSTON and SAN FRANCISCO, April 18, 2018 – Pear Therapeutics, Inc. today announced a deal with Sandoz, a division of Novartis, to commercialize its two lead products, reSET® and reSET-O™. In addition to an upfront payment, the deal includes research and development funding, commercial milestones, and a profit split on net sales of both therapeutics.

Click here for the full press release.

Pear Therapeutics to Present at 38th Annual Cowen Health Care Conference

Boston, March 6, 2018 – Pear Therapeutics, Inc., the leader in prescription digital therapeutics, today announced that Corey McCann, M.D., Ph.D., President and CEO, will present at the Cowen Health Care Conference on Tuesday, March 13, 2018, at 12:30 p.m. ET at the Boston Marriott Copley Place in Boston.

Click here for the full PEAR release…

PEAR Therapeutics to Collaborate with Novartis to Develop Prescription Digital Therapeutics

BOSTON, and SAN FRANCISCO, March 1, 2018—PEAR Therapeutics announced today that it has entered into a collaboration with Novartis to develop novel prescription digital therapeutics for schizophrenia and multiple sclerosis (MS). These digital therapeutics are software applications designed to effectively improve clinical outcomes for patients. The collaboration brings together Novartis’ expertise in neurological disorders, clinical development, and commercialization with PEAR’s leading experience in prescription digital therapeutic design and implementation.

Click here for the full PEAR Press Release … 

 

PEAR Therapeutics to Participate in BIO CEO & Investor Conference and LEERINK Partners 7th Annual Global Healthcare Conference

BOSTON, and SAN FRANCISCO, February 6, 2018—PEAR Therapeutics, the leader in prescription digital therapeutics, today announced that Corey McCann, M.D., Ph.D., President and CEO of PEAR Therapeutics, will present a company update at the annual BIO CEO & Investor Conference taking place on Tuesday, February 13, 2018, at the New York Marriott Marquis in New York. The company also will participate in the LEERINK Partners 7th Annual Global Healthcare Conference taking place February 14-15, 2018, at the Lotte New York Palace Hotel in New York.

Click here for the full PEAR Press Release…

PEAR Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference

BOSTON, and SAN FRANCISCO, January 3, 2018—PEAR Therapeutics, the leader in prescription digital therapeutics, today announced that Corey McCann, M.D., Ph.D., President and CEO of PEAR Therapeutics, will present at the annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 at 5:00 pm PST at the Westin St. Francis in San Francisco.

Click here for the full PEAR Press Release…

PEAR Therapeutics Completes $50 Million Series B Financing

BOSTON, and SAN FRANCISCO, January 2, 2018– PEAR Therapeutics, the leader in prescription digital therapeutics, today announced that it has successfully closed a $50 million Series B financing led by Temasek. With this financing, Temasek joins new and existing investors including 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, Singapore-based EDBI, and the Bridge Builder’s Collaborative. PEAR is the first company to receive U.S. Food and Drug Administration (FDA) clearance for a prescription digital therapeutic with claims to improve clinical outcomes in a disease. The financing will allow the company to commercialize its lead programs and further develop its pipeline and platform.

Click here for the full PEAR Press Release…

Pear Therapeutics Wins Fierce Innovation Life Science Award for reSET® Prescription Digital Therapeutic

BOSTON, and SAN FRANCISCO, December 12, 2017 – Pear Therapeutics, the leader in prescription digital therapeutics, has won a Fierce Innovation Award in the Digital Health Solution category for reSET®, the first FDA-cleared prescription digital therapeutic to treat any disease. In randomized clinical studies, reSET demonstrated improvement in the outcomes of abstinence and treatment retention in patients with substance use disorder (SUD). Pear was also selected as “Best in Show” for Best Outsourcing Partner.

Click here for the full PEAR Press Release…

Pear Therapeutics Receives Expedited Access Pathway Designation from FDA for reSET-OTM Prescription Digital Therapeutic to Treat Opioid Use Disorder

BOSTON, and SAN FRANCISCO, October 18, 2017—Pear Therapeutics, the leader in prescription digital therapeutics, today announced that it has received an Expedited Access Pathway (EAP) designation from the U.S. Food and Drug Administration (FDA) for its reSET-OTM Prescription Digital Therapeutic, the first of its kind designed for treating Opioid Use Disorder (OUD).

“The opioid epidemic continues to ravage cities and towns across this country with officials estimating even higher numbers of overdoses in 2017,” said Corey McCann, M.D., Ph.D., President and Chief Executive Officer of Pear Therapeutics. “With states struggling to provide treatment resources, we firmly believe that prescription digital therapeutics will change the way we address opioid dependence. We applaud the FDA for recognizing the need to bring innovative new treatment options to patients and clinicians and we look forward to closely working with them under the EAP program to accelerate access to reSET-O.”

Click here for the full PEAR Press Release…